Thursday evening, the U.S. Food and Drug Administration approved AstraZeneca 's Arimidex for use against early-stage breastcancerin post-menopausal women.
Professor MARCY DEVEAUX (Journalism, California State University Northridge): Finding breastcancer so early now that they had to put a stagein between zero and one.
And now, the drug, in combination with the chemotherapy Taxol, allows patients with early-stage breastcancer an average of four months without their disease progressing.